The HIV treatment landscape is constantly evolving, with new and improved regimens easing the once-mighty burden of daily antiretroviral treatment, according to new data presented at the 10th International AIDS Society (IAS) Conference on HIV Science in Mexico City last week.
Two-drug therapy -- once considered a pipe dream because of the apparent risk of antiretroviral resistance -- may in fact be realistic for some patients, according to two major presentations at IAS. Meanwhile, researchers from France have tested the theory that it's safe for some patients to take short "breaks," essentially skipping a few doses of antiretroviral regimens each week. This strategy could improve patient safety by lowering the amount of drug patients are exposed to over their lifetimes.
And, new data on the investigational therapy MK-8591, an injectable nucleoside reverse transcriptase translocation inhibitor (NRTTI), demonstrated sustained viral response in combination with doravirine (Pifeltro, also called DOR), a recently approved NNRTI.